Patient Selection by Tumor Markers in Liver Transplantation for Advanced Hepatocellular Carcinoma

Hae Won Lee, Gi Won Song, Sung Gyu Lee, Jong Man Kim, Jae Won Joh, Dai Hoon Han, Soon Il Kim, Seong Hoon Kim, Dong-Sik Kim, Jai Young Cho, Kyung Suk Suh

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Although far advanced hepatocellular carcinoma (HCC) is generally considered a contraindication for liver transplantation (LT), biologically favorable tumors among them could show acceptable results. However, it is still unclear which tumors can be treated with LT. Data were collected on adult patients who underwent LT for HCC beyond the Milan criteria in 8 Korean LT centers between January 2000 and June 2013. Far advanced HCC was defined as HCC with the largest tumor ≥ 10 cm, 10 or more tumor nodules, or accompanying macrovascular invasion. A total of 688 patients, including 169 with far advanced HCC, were enrolled in this study. The 5-year overall and recurrence-free survival rates were 60.4% and 55.1%, respectively, for all patients but only 28.7% and 24.8%, respectively, for patients with far advanced HCC (P < 0.001). Both preoperative alpha-fetoprotein (AFP) and protein induced by vitamin K absence or antagonist II (PIVKA-II) were significant risk factors for HCC recurrence after LT. In particular, AFP + PIVKA-II combined was a better predictor than either marker alone. Of all far advanced HCC patients with available AFP and PIVKA-II levels, 45 (30.8%) had low AFP + PIVKA-II (≤300) and their 5-year overall and recurrence-free survival rate were 47.8% and 53.4%, respectively, which were acceptable and significantly superior to those of patients with AFP (ng/mL) + PIVKA-II (nAU/mL) > 300 (21.0% and 10.8%, respectively; P < 0.001). In conclusion, patients with favorable HCC had acceptable outcomes after LT even when their tumors were extremely advanced. AFP + PIVKA-II gave reliable information about the tumor biology of far advanced HCC. Liver Transplantation 00 000–000 2018 AASLD.

Original languageEnglish
Pages (from-to)1243-1251
Number of pages9
JournalLiver Transplantation
Volume24
Issue number9
DOIs
Publication statusPublished - 2018 Sep 1

Fingerprint

Tumor Biomarkers
Liver Transplantation
Patient Selection
Hepatocellular Carcinoma
Neoplasms
Survival Rate
Recurrence

ASJC Scopus subject areas

  • Surgery
  • Hepatology
  • Transplantation

Cite this

Lee, H. W., Song, G. W., Lee, S. G., Kim, J. M., Joh, J. W., Han, D. H., ... Suh, K. S. (2018). Patient Selection by Tumor Markers in Liver Transplantation for Advanced Hepatocellular Carcinoma. Liver Transplantation, 24(9), 1243-1251. https://doi.org/10.1002/lt.25056

Patient Selection by Tumor Markers in Liver Transplantation for Advanced Hepatocellular Carcinoma. / Lee, Hae Won; Song, Gi Won; Lee, Sung Gyu; Kim, Jong Man; Joh, Jae Won; Han, Dai Hoon; Kim, Soon Il; Kim, Seong Hoon; Kim, Dong-Sik; Cho, Jai Young; Suh, Kyung Suk.

In: Liver Transplantation, Vol. 24, No. 9, 01.09.2018, p. 1243-1251.

Research output: Contribution to journalArticle

Lee, HW, Song, GW, Lee, SG, Kim, JM, Joh, JW, Han, DH, Kim, SI, Kim, SH, Kim, D-S, Cho, JY & Suh, KS 2018, 'Patient Selection by Tumor Markers in Liver Transplantation for Advanced Hepatocellular Carcinoma', Liver Transplantation, vol. 24, no. 9, pp. 1243-1251. https://doi.org/10.1002/lt.25056
Lee, Hae Won ; Song, Gi Won ; Lee, Sung Gyu ; Kim, Jong Man ; Joh, Jae Won ; Han, Dai Hoon ; Kim, Soon Il ; Kim, Seong Hoon ; Kim, Dong-Sik ; Cho, Jai Young ; Suh, Kyung Suk. / Patient Selection by Tumor Markers in Liver Transplantation for Advanced Hepatocellular Carcinoma. In: Liver Transplantation. 2018 ; Vol. 24, No. 9. pp. 1243-1251.
@article{1138644347524c3e8f81f23c614a08e5,
title = "Patient Selection by Tumor Markers in Liver Transplantation for Advanced Hepatocellular Carcinoma",
abstract = "Although far advanced hepatocellular carcinoma (HCC) is generally considered a contraindication for liver transplantation (LT), biologically favorable tumors among them could show acceptable results. However, it is still unclear which tumors can be treated with LT. Data were collected on adult patients who underwent LT for HCC beyond the Milan criteria in 8 Korean LT centers between January 2000 and June 2013. Far advanced HCC was defined as HCC with the largest tumor ≥ 10 cm, 10 or more tumor nodules, or accompanying macrovascular invasion. A total of 688 patients, including 169 with far advanced HCC, were enrolled in this study. The 5-year overall and recurrence-free survival rates were 60.4{\%} and 55.1{\%}, respectively, for all patients but only 28.7{\%} and 24.8{\%}, respectively, for patients with far advanced HCC (P < 0.001). Both preoperative alpha-fetoprotein (AFP) and protein induced by vitamin K absence or antagonist II (PIVKA-II) were significant risk factors for HCC recurrence after LT. In particular, AFP + PIVKA-II combined was a better predictor than either marker alone. Of all far advanced HCC patients with available AFP and PIVKA-II levels, 45 (30.8{\%}) had low AFP + PIVKA-II (≤300) and their 5-year overall and recurrence-free survival rate were 47.8{\%} and 53.4{\%}, respectively, which were acceptable and significantly superior to those of patients with AFP (ng/mL) + PIVKA-II (nAU/mL) > 300 (21.0{\%} and 10.8{\%}, respectively; P < 0.001). In conclusion, patients with favorable HCC had acceptable outcomes after LT even when their tumors were extremely advanced. AFP + PIVKA-II gave reliable information about the tumor biology of far advanced HCC. Liver Transplantation 00 000–000 2018 AASLD.",
author = "Lee, {Hae Won} and Song, {Gi Won} and Lee, {Sung Gyu} and Kim, {Jong Man} and Joh, {Jae Won} and Han, {Dai Hoon} and Kim, {Soon Il} and Kim, {Seong Hoon} and Dong-Sik Kim and Cho, {Jai Young} and Suh, {Kyung Suk}",
year = "2018",
month = "9",
day = "1",
doi = "10.1002/lt.25056",
language = "English",
volume = "24",
pages = "1243--1251",
journal = "Liver Transplantation",
issn = "1527-6465",
publisher = "John Wiley and Sons Ltd",
number = "9",

}

TY - JOUR

T1 - Patient Selection by Tumor Markers in Liver Transplantation for Advanced Hepatocellular Carcinoma

AU - Lee, Hae Won

AU - Song, Gi Won

AU - Lee, Sung Gyu

AU - Kim, Jong Man

AU - Joh, Jae Won

AU - Han, Dai Hoon

AU - Kim, Soon Il

AU - Kim, Seong Hoon

AU - Kim, Dong-Sik

AU - Cho, Jai Young

AU - Suh, Kyung Suk

PY - 2018/9/1

Y1 - 2018/9/1

N2 - Although far advanced hepatocellular carcinoma (HCC) is generally considered a contraindication for liver transplantation (LT), biologically favorable tumors among them could show acceptable results. However, it is still unclear which tumors can be treated with LT. Data were collected on adult patients who underwent LT for HCC beyond the Milan criteria in 8 Korean LT centers between January 2000 and June 2013. Far advanced HCC was defined as HCC with the largest tumor ≥ 10 cm, 10 or more tumor nodules, or accompanying macrovascular invasion. A total of 688 patients, including 169 with far advanced HCC, were enrolled in this study. The 5-year overall and recurrence-free survival rates were 60.4% and 55.1%, respectively, for all patients but only 28.7% and 24.8%, respectively, for patients with far advanced HCC (P < 0.001). Both preoperative alpha-fetoprotein (AFP) and protein induced by vitamin K absence or antagonist II (PIVKA-II) were significant risk factors for HCC recurrence after LT. In particular, AFP + PIVKA-II combined was a better predictor than either marker alone. Of all far advanced HCC patients with available AFP and PIVKA-II levels, 45 (30.8%) had low AFP + PIVKA-II (≤300) and their 5-year overall and recurrence-free survival rate were 47.8% and 53.4%, respectively, which were acceptable and significantly superior to those of patients with AFP (ng/mL) + PIVKA-II (nAU/mL) > 300 (21.0% and 10.8%, respectively; P < 0.001). In conclusion, patients with favorable HCC had acceptable outcomes after LT even when their tumors were extremely advanced. AFP + PIVKA-II gave reliable information about the tumor biology of far advanced HCC. Liver Transplantation 00 000–000 2018 AASLD.

AB - Although far advanced hepatocellular carcinoma (HCC) is generally considered a contraindication for liver transplantation (LT), biologically favorable tumors among them could show acceptable results. However, it is still unclear which tumors can be treated with LT. Data were collected on adult patients who underwent LT for HCC beyond the Milan criteria in 8 Korean LT centers between January 2000 and June 2013. Far advanced HCC was defined as HCC with the largest tumor ≥ 10 cm, 10 or more tumor nodules, or accompanying macrovascular invasion. A total of 688 patients, including 169 with far advanced HCC, were enrolled in this study. The 5-year overall and recurrence-free survival rates were 60.4% and 55.1%, respectively, for all patients but only 28.7% and 24.8%, respectively, for patients with far advanced HCC (P < 0.001). Both preoperative alpha-fetoprotein (AFP) and protein induced by vitamin K absence or antagonist II (PIVKA-II) were significant risk factors for HCC recurrence after LT. In particular, AFP + PIVKA-II combined was a better predictor than either marker alone. Of all far advanced HCC patients with available AFP and PIVKA-II levels, 45 (30.8%) had low AFP + PIVKA-II (≤300) and their 5-year overall and recurrence-free survival rate were 47.8% and 53.4%, respectively, which were acceptable and significantly superior to those of patients with AFP (ng/mL) + PIVKA-II (nAU/mL) > 300 (21.0% and 10.8%, respectively; P < 0.001). In conclusion, patients with favorable HCC had acceptable outcomes after LT even when their tumors were extremely advanced. AFP + PIVKA-II gave reliable information about the tumor biology of far advanced HCC. Liver Transplantation 00 000–000 2018 AASLD.

UR - http://www.scopus.com/inward/record.url?scp=85053843079&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85053843079&partnerID=8YFLogxK

U2 - 10.1002/lt.25056

DO - 10.1002/lt.25056

M3 - Article

C2 - 29575509

AN - SCOPUS:85053843079

VL - 24

SP - 1243

EP - 1251

JO - Liver Transplantation

JF - Liver Transplantation

SN - 1527-6465

IS - 9

ER -